Sapient Capital LLC Has $1.91 Million Position in Stryker Corporation $SYK

Sapient Capital LLC raised its position in Stryker Corporation (NYSE:SYK) by 168.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,044 shares of the medical technology company’s stock after purchasing an additional 3,794 shares during the quarter. Sapient Capital LLC’s holdings in Stryker were worth $1,908,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Premier Path Wealth Partners LLC raised its holdings in Stryker by 10.8% in the 2nd quarter. Premier Path Wealth Partners LLC now owns 2,001 shares of the medical technology company’s stock valued at $630,000 after buying an additional 195 shares during the last quarter. NEOS Investment Management LLC increased its position in Stryker by 12.4% in the 2nd quarter. NEOS Investment Management LLC now owns 55,637 shares of the medical technology company’s stock valued at $17,517,000 after acquiring an additional 6,146 shares during the period. AXQ Capital LP raised its stake in shares of Stryker by 35.8% during the second quarter. AXQ Capital LP now owns 1,944 shares of the medical technology company’s stock valued at $612,000 after acquiring an additional 513 shares during the last quarter. KFG Wealth Management LLC raised its stake in shares of Stryker by 10.4% during the second quarter. KFG Wealth Management LLC now owns 1,737 shares of the medical technology company’s stock valued at $547,000 after acquiring an additional 163 shares during the last quarter. Finally, Strengthening Families & Communities LLC lifted its holdings in shares of Stryker by 0.7% during the second quarter. Strengthening Families & Communities LLC now owns 7,750 shares of the medical technology company’s stock worth $2,440,000 after purchasing an additional 52 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on SYK shares. Truist Financial increased their price objective on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Citigroup reiterated a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. Citizens Jmp lowered their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Raymond James Financial set a $370.00 price objective on Stryker in a research note on Friday, July 31st. Finally, BTIG Research reduced their target price on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Performance

SYK stock opened at $302.92 on Friday. The stock has a 50-day moving average price of $328.84 and a 200-day moving average price of $329.73. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.37. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market cap of $116.19 billion, a PE ratio of 31.39, a price-to-earnings-growth ratio of 1.93 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the business earned $3.13 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 15.03 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s payout ratio is 36.48%.

Insiders Place Their Bets

In related news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. This represents a 11.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 351,267 shares of company stock worth $118,197,701. Corporate insiders own 4.60% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.